CoroPrevention - Personalised Prevention for Coronary Heart Disease

European Coronary Heart Disease (CHD) burden remains unsustainable. Better risk stratification tools and personalized care of patients are needed for reducing morbidity and mortality of CHD and the associated economic burden. To this end we are developing a strategy to shape and implement a personalized secondary prevention strategy for patients with established CHD. This precision strategy will be tested in a prospective trial, the CoroPrevention Trial, a central element of our ambitious proposal. The project results can be used to upgrade current CHD guidelines towards personalized care and project partner European Society of Cardiology (ESC) will disseminate the new knowledge and educate physicians and patients across Europe.  

We are aiming to prospectively evaluate the clinical utility of personalized prevention in CHD as well as  health economic and social benefits of the personalized prevention in CHD. In addition, we aim to discover predictive markers of drug treatment responses in CHD and provide novel data for guideline committees allowing improvements to current CHD guidelines based on CoroPrevention RCT validated prospective clinical data. Finally, we will disseminate the refined prevention program to the attention of practitioners, patients, health care payers and policy makers.

MET faculty's role in the project:

Tampere University, Faculty of Medicine and Health Technology (MET) is the scientific coordinator of the CoroPrevention project and act as the sponsor of the CoroPrevention RCT.

Our CoroPrevention project will provide both quantitative and qualitative indicators for CHD patient risk stratification and personalized prevention across Europe allowing informed decisions on the organizations of healthcare systems. Our aim is to permanently change the current preventive care practice in CHD by improving risk identification, non-medical prevention methods and drug targeting to patients with treatment benefits. Results from the RCT will ensure that each CVD patient receives the optimal treatment already from the beginning rather than having to go through a process of trial and error. Improved treatments will improve patients’ quality of life and reduce the societal costs associated with CVD. A more advanced and patient-specific stratification model will lead to better prevention, more precise diagnosis, improved treatment and thus less rehabilitation and long-term care.

Tampere University, Faculty of Medicine and Health Technology

Reijo Laaksonen
Research Director
Tampere University, Faculty of Medicine and Health Technology
Arvo Ylpön katu 34, 33520 Tampere, Finland
Email: coroprevention [at] tuni.fi (coroprevention[at]tuni[dot]fi)